The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 11, 2012
Filed:
Sep. 14, 2009
Show-wen Liu, Shetou Township, Changhua County, TW;
Cheng-hsien Lin, Taipei, TW;
Tsyh-lang Lin, Bade, TW;
Cheng-fang Hsu, Toufen Township, Miaoli County, TW;
Show-Wen Liu, Shetou Township, Changhua County, TW;
Cheng-Hsien Lin, Taipei, TW;
Tsyh-Lang Lin, Bade, TW;
Cheng-Fang Hsu, Toufen Township, Miaoli County, TW;
Atomic Energy Council-Institute of Nuclear Energy Research, Taoyuan County, TW;
Abstract
HLMN series compounds used as radioactive agents for treatment of liver cancer and a manufacturing method thereof are revealed. 2-thioethylamine hydrochloride is reacted with triphenylmethanol for protection of thiol to obtain 2-[(triphenylmethyl)thio]ethylamine. Then obtain N-[2-((triphenylmethyl)thio)ethyl]chloroacetamide by a transamidation reaction between 2-[(triphenylmethyl)thio]ethylamine and chloroactyl chloride. Next produce a amine-amide-thiol ligand-N-[2-((triphenylmethyl)thio)ethyl][2-((triphenylmethyl)thio)ethylamino]acetamide by a substitution reaction of N-[2-((triphenylmethyl)thio)ethyl]chloroacetamide and 2-[(triphenylmethyl)thio]ethylamine. After respective reaction with 1-bromotetradecane, 1-bromohexadecane and ethyl 16-bromohexadecanoate, HLMN series compounds are obtained. These amine-amide-dithiols quadridentate ligands can react with MO(M=Tc or Re) to produce electrically neutral complexes. The complexes have high lipophilicity, allowing them soluble in lipiodol to be applied to radiation therapy for liver cancer.